A Phase I, dose-escalating study of safety and pharmacokinetics of inhaled dry powder vancomycin (AeroVanc) in volunteers and patients with cystic fibrosis: a new approach to therapy for methicillin-resistant Staphylococcus aureus.
In conclusion, AeroVanc was well tolerated and achieved high levels in sputum with a mean systemic absorption of 49%, making it a potential therapeutic strategy for respiratory infection with MRSA.
PMID: 31964790 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Waterer G, Lord J, Hofmann T, Jouhikainen T Tags: Antimicrob Agents Chemother Source Type: research
More News: Chemotherapy | Cystic Fibrosis | Infectious Diseases | Microbiology | MRSA | Respiratory Medicine | Staphylococcus Aureus | Study | Superbugs | Toxicology